title: Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
abstract: BACKGROUND
  Classically activated macrophages produce IL-12, IL-23, and TNF-α, whereas alternatively activated macrophages (M2 cells) produce IL-10 and express several receptors such as mannose receptor and CD163. Tumor-associated macrophages exhibit M2 phenotype, whose presence has been associated with poor prognosis in various tumors.
  
  
  OBJECTIVE
  To investigate distribution of CD163(+) cells in lesional skin and serum levels of soluble CD163 (sCD163) in patients with cutaneous T cell lymphoma (CTCL), atopic dermatitis (AD), or psoriasis.
  
  
  METHODS
  The numbers of CD163(+) and CD68(+) cells in lesional skin of CTCL, AD, or psoriasis, and in normal skin were examined by immunohistochemistry. Serum soluble CD163 (sCD163) levels were quantified by enzyme-linked immunosorbent assay.
  
  
  RESULTS
  The numbers of CD163(+) cells in lesional skin of CTCL, AD, or psoriasis were significantly larger than in normal skin. In CTCL, the numbers of CD163(+) or CD68(+) cells increased as more tumor cells infiltrated and they decreased after treatment with topical steroid and ultraviolet light. Moreover, CTCL patients with an increased number of CD163(+) cells showed worse prognosis. Serum sCD163 levels in patients with CTCL, AD, or psoriasis were significantly higher than those in normal controls. In CTCL patients, serum sCD163 levels significantly correlated with serum soluble interleukin-2 receptor and CCL17 levels. In AD patients, serum sCD163 levels correlated with serum IgE levels.
  
  
  CONCLUSIONS
  The numbers of CD163(+) cells in lesional skin and serum sCD163 levels were associated with disease progression of CTCL. Further study focusing on CD163(+) cells in CTCL lesional skin would be an interesting research field.
authors.affiliation: Department of Dermatology, University of Tokyo, Tokyo, Japan. sugayam-der@h.u-tokyo.ac.jp
authors.forename: Makoto
authors.initials: M
authors.lastname: Sugaya
authors.forename: Tomomitsu
authors.initials: T
authors.lastname: Miyagaki
authors.forename: Hanako
authors.initials: H
authors.lastname: Ohmatsu
authors.forename: Hiraku
authors.initials: H
authors.lastname: Suga
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Kai
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kamata
authors.forename: Hideki
authors.initials: H
authors.lastname: Fujita
authors.forename: Yoshihide
authors.initials: Y
authors.lastname: Asano
authors.forename: Yayoi
authors.initials: Y
authors.lastname: Tada
authors.forename: Takafumi
authors.initials: T
authors.lastname: Kadono
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Okochi
authors.forename: Shinichi
authors.initials: S
authors.lastname: Sato
mesh_terms: D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000097:blood / Q000378:metabolism*; D015214:Antigens, Differentiation, Myelomonocytic / Q000097:blood / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000097:blood / Q000378:metabolism*; D054414:Chemokine CCL17 / Q000097:blood; D003876:Dermatitis, Atopic / Q000097:blood / Q000276:immunology; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D016410:Lymphoma, T-Cell, Cutaneous / Q000097:blood / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008262:Macrophage Activation; D008264:Macrophages / Q000276:immunology* / Q000473:pathology; D008875:Middle Aged; D010641:Phenotype; D011565:Psoriasis / Q000097:blood / Q000276:immunology; D011956:Receptors, Cell Surface / Q000097:blood / Q000378:metabolism*; D015375:Receptors, Interleukin-2 / Q000097:blood; D012867:Skin / Q000276:immunology* / Q000473:pathology; D012878:Skin Neoplasms / Q000097:blood / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D016896:Treatment Outcome; D055815:Young Adult; D000098902:CD163 Antigen; D000097382:CD68 Molecule
chemical_list: D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D014408:Biomarkers, Tumor; D054414:Chemokine CCL17; D007073:Immunoglobulin E; D011956:Receptors, Cell Surface; D015375:Receptors, Interleukin-2; D000098902:CD163 Antigen; C106230:CCL17 protein, human; C067980:CD68 antigen, human; D000097382:CD68 Molecule